Table 20.
Histopathology | N | Deaths | Median Survival (95% CI) |
---|---|---|---|
Diffuse astrocytoma | 24,819 | 13,755 | 63 (60-66) |
Anaplastic astrocytoma | 17,735 | 12,514 | 21 (20-21) |
Glioblastoma | 146,320 | 131,036 | 8 (8-9) |
Oligodendroglioma | 11,926 | 3,780 | 205 (196-209) |
Anaplastic oligodendroglioma | 5,339 | 2,533 | 108 (101-116) |
Oligoastrocytic tumors | 6,617 | 3,504 | 113 (107-120) |
Pilocytic astrocytoma | 312 | 1 | *** (**-**) |
Unique astrocytoma variants | 2,484 | 422 | ** (**-**) |
Ependymal tumors | 18,645 | 3,407 | ** (**-**) |
Glioma malignant, NOS | 20,839 | 10,035 | 95 (86-104) |
Choroid plexus tumors | 2,285 | 358 | ** (**-**) |
Other neuroepithelial tumors | 280 | 84 | 215 (198-**) |
Neuronal and mixed neuronal-glial tumors | 12,725 | 1,619 | ** (**-**) |
Tumors of the pineal region | 1,948 | 538 | ** (216-**) |
Embryonal tumors | 10,595 | 4,204 | ** (**-**) |
Medulloblastoma | 7,007 | 2,075 | ** (**-**) |
Atypical teratoid/rhabdoid tumor | 1,129 | 726 | 14 (12-17) |
Other embryonal tumors | 2,459 | 1,403 | 43 (36-50) |
Nerve sheath tumors | 89,222 | 9,235 | ** (**-**) |
Other tumors of cranial and spinal nerves | 69 | 8 | ** (**-**) |
Meningiomas | 398,870 | 114,855 | 184 (181-186) |
Mesenchymal tumors | 16,523 | 3,054 | ** (**-**) |
Primary melanocytic lesions | 282 | 171 | 30 (22-60) |
Lymphoma | 20,028 | 13,624 | 16 (16-18) |
Other hematopoietic neoplasms | 196 | 96 | 138 (94-**) |
Germ cell tumor | 3,601 | 529 | ** (**-**) |
Tumors of the pituitary | 179,087 | 22,448 | ** (**-**) |
Craniopharyngioma | 7,997 | 1,724 | ** (**-**) |
Hemangioma | 8,891 | 1,029 | ** (**-**) |
Neoplasm, unspecified | 29,036 | 16,254 | 45 (42-49) |
All other | 1,285 | 222 | ** (**-**) |
* ** Cannot be calculated due to median survival not being observed.
-- Survival estimates are not presented when fewer than 100 cases were reported for the specific category.
Abbreviations: CBTRUS, Central Brian Tumor Registry of the United States; CI, confidence interval; NOS, not otherwise specified; NPCR, National Program of Cancer Registries; SEER, Surveillance, Epidemiology, and End Results Program.